Clinical Trials at Winship Cancer Institute of Emory University
As of June 2026, 40 paid clinical trials are recruiting at Winship Cancer Institute of Emory University, located at 1365C CLIFTON RD NE, SUITE C2056, ATLANTA, GA 30322-1013, phone (404) 778-1900 in Atlanta, Georgia. Active studies at this site cover conditions such as Multiple Myeloma, Breast Cancer and Schizophrenia. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
40 clinical trials at Winship Cancer Institute of Emory University
·Clear filters·↓ Download CSVStudy of INCA036978 in Participants With Myeloproliferative Neoplasms
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
A Long-Term Follow-Up Basket Study for Participants Treated With SynKIR Chimeric Antigen Receptor (CAR) T Cell Product
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
SynKIR-310 for Relapsed/Refractory B-NHL
ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer
A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma
Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
Evaluation of Lymphoma Prognosis and Survivorship in Recently Diagnosed Patients, LEO Study
DALY II USA/ MB-CART2019.1 for DLBCL
Personalized Autologous Transplant for Multiple Myeloma
DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
About research studies in Atlanta
Atlanta has approximately 1,545 recruiting research studies across a wide range of therapeutic areas. Georgia is home to Emory University Hospital, Winship Cancer Institute, and Children's Healthcare of Atlanta, with active research in oncology, infectious disease, and cardiovascular health.
Common conditions studied in Atlanta
- Multiple Myeloma (30 active studies). Recruiting Multiple Myeloma studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Breast Cancer (24 active studies). Breast cancer trials evaluate new hormone therapies, targeted drugs, and immunotherapy combinations aimed at improving survival and reducing recurrence.
- Schizophrenia (20 active studies). Schizophrenia research tests muscarinic agonists, long-acting injectable antipsychotics, and cognitive remediation therapies.
- Heart Failure (19 active studies). Heart failure trials explore SGLT-2 inhibitors, novel myosin modulators, and device-based therapies for both reduced and preserved ejection fraction.
- Sickle Cell Disease (17 active studies). Sickle cell disease studies test gene therapies, gene editing, and new small molecules aimed at reducing pain crises and organ damage.
- Acute Myeloid Leukemia (16 active studies). Leukemia trials evaluate targeted inhibitors, CAR-T cell therapies, and novel combinations for acute and chronic forms of the disease.
Leading research sponsors in Atlanta
- Emory University
- National Cancer Institute (NCI)
- AstraZeneca
- Children's Oncology Group
- Eli Lilly and Company
Local regulations and guidelines
Clinical trials in Georgia are governed by U.S. Food and Drug Administration (FDA) regulations, Office for Human Research Protections (OHRP) standards, and federal HIPAA privacy rules. Every study is reviewed by an Institutional Review Board (IRB) to protect participant safety and ensure informed consent. Georgia research additionally follows state public health department oversight and any applicable state privacy statutes.
Compensation & what to expect
- How payment typically works
- Compensation is most often provided through reloadable electronic study cards or direct deposit, paid out per completed visit rather than as a lump sum. Amounts vary by the time required, the number of visits, and the study's complexity — overnight stays and inpatient pharmacology studies generally pay more than short outpatient surveys. The exact amount is disclosed in writing during informed consent before any visit.
- Healthy volunteers
- Healthy participants aged 18 and older can earn compensation by joining vaccine, pharmacology, and biomarker studies in Atlanta. These trials check how a new drug or vaccine behaves in healthy bodies before later-phase testing. Many sites maintain a healthy-volunteer registry so you hear about new opportunities first.
- What's included beyond payment
- Most trials cover study-related medical care at no cost — physical exams, lab work, imaging, the investigational treatment itself, and follow-up visits with the research team. Insurance is not required to participate. Free check-ups and access to specialists are common reasons participants return for additional studies.
- Travel and time
- Many sponsors reimburse travel, parking, mileage, and lost wages for visit days. Long-running studies and trials that require frequent visits often raise stipends accordingly. Ask the study coordinator for the visit schedule and reimbursement policy before you commit.
- Asking about compensation
- Compensation is set per protocol and per site, so figures are not published in trial registries. The fastest way to confirm payment for a specific study is to contact the recruiting site listed on the study record. Coordinators are accustomed to this question and will quote the per-visit and total amounts up front.
How to find a clinical trial in Atlanta
Hipa.ai aggregates every recruiting study in Atlanta from ClinicalTrials.gov and refreshes the list daily. Use the filters above to narrow by condition, facility, age, phase, or healthy-volunteer eligibility, then click any study title to view full details — eligibility criteria, intervention, location, and sponsor contact information. To enroll, reach out to the central study contact listed on the study detail page; the research coordinator will walk you through the screening process.
Frequently asked questions
How many paid clinical trials are currently recruiting in Atlanta?
There are approximately 1,545 recruiting clinical trials in Atlanta, Georgia listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Atlanta pay participants?
Most recruiting trials in Atlanta compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Atlanta?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Atlanta?
The most common conditions under active study in Atlanta include Multiple Myeloma (30), Breast Cancer (24), Schizophrenia (20), Heart Failure (19), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Atlanta?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Atlanta on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Atlanta?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Atlanta?
Recruiting research sites in Atlanta include Emory University, Emory University Hospital/Winship Cancer Institute, Emory University Hospital Midtown, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Atlanta right now?
The largest active categories in Atlanta are Cancer & tumors (472), Cardiovascular (104), Neurology & pain (92). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of Winship Cancer Institute of Emory University?
Winship Cancer Institute of Emory University is located at 1365C CLIFTON RD NE, SUITE C2056, ATLANTA, GA 30322-1013. Use the Google Maps link in the intro above to get directions.
How do I contact Winship Cancer Institute of Emory University?
You can reach Winship Cancer Institute of Emory University by phone at (404) 778-1900. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.